JiangXi Tianxin Pharm Co Ltd

Tianxin Pharmaceutical released its 2026 interim report. During the reporting period, total operating revenue was 1.309 billion yuan, and net profit attributable to the parent company was 319 million yuan, a decrease of 36.6888 million yuan compared with the same period last year, down 10.31% year-on-year. Net cash inflow from operating activities was 384 million yuan, the asset-liability ratio was 22.43%, the gross margin was 41.07%, and diluted earnings per share was 0.73 yuan, down 10.98% year-on-year. The number of shareholders was 11,400, and the top ten shareholders held 91.19% of the total share capital.